Evidence map›Paper›PMID 22929886›Full record

ArticleBritish journal of cancer2012

MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer.

S Ali, H Saleh, S Sethi, F H Sarkar, P A Philip

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 4 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 4 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Pancreatic Cancer: Genetic Conditions and Epigenetic Alterations.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Review
  8. Article
  9. Influence of Micro-RNA-423 Gene Variation on Risk and Characteristics of Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2022
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

S AliDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
H Saleh
S Sethi
F H Sarkar
P A Philip
Wayne State University · USThe Barbara Ann Karmanos Cancer Institute · US

Funding

RO1: A novel and targeted approach to inhibit invasion and angiogenesisR01CA131151 · NCI · WAYNE STATE UNIVERSITY · PI SARKAR, FAZLUL H. · 2008 to 2012
$1.8M
Prevention of Tumor Progression by a Novel ApproachR01CA154321 · NCI · WAYNE STATE UNIVERSITY · PI SARKAR, FAZLUL H. · 2011 to 2015
$1.5M
FoxM1: A molecular target in pancreatic cancerR01CA132794 · NCI · WAYNE STATE UNIVERSITY · PI SARKAR, FAZLUL H. · 2009 to 2013
$1.5M
NCI NIH HHS 1R01CA154321NCI NIH HHS 3R01CA131151-02S1NCI NIH HHS 5R01CA131151NCI NIH HHS 5R01CA132794NCI NIH HHS R01 CA131151NCI NIH HHS R01 CA132794NCI NIH HHS R01 CA154321
6 · The paper itself

Abstract

backgroundA major challenge to the development of biomarkers for pancreatic cancer (PC) is the small amount of tissue obtained at the time of diagnosis. Single-gene analyses may not reliably predict biology of PC because of its complex molecular makeup. MicroRNA (miRNA) profiling may provide a more informative molecular interrogation of tumours. The primary objective of this study was to determine the feasibility of performing miRNA arrays and quantitative real-time PCR (qRT-PCR) from archival formalin-fixed paraffin-embedded (FFPE) cell blocks obtained from fine-needle aspirates (FNAs) that is the commonest diagnostic procedure for suspected PC.

methodsMicroRNA expression profiling was performed on FFPE from FNA of suspicious pancreatic masses. Subjects included those who had a pathological diagnosis of pancreatic adenocarcinoma and others with a non-malignant pancreatic histology. Exiqon assay was used to quantify miRNA levels and qRT-PCR was used to validate abnormal expression of selected miRNAs.

resultsA total of 29 and 15 subjects had pancreatic adenocarcinoma and no evidence of cancer, respectively. The RNA yields per patient varied from 25 to 100 ng. Profiling demonstrated deregulation of over 228 miRNAs in pancreatic adenocarcinoma of which the top 7 were further validated by qRT-PCR. The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients. MicroRNAs let-7d and miR-423-5p was either downregulated or upregulated with a significant inter-individual variation in their expression.

conclusionThis study demonstrated the feasibility of using archival FFPE cell blocks from FNAs to establish RNA-based molecular signatures unique to pancreatic adenocarcinoma with potential applications in clinical trials for risk stratification, patient selection, and target validation.

Indexed as

AdenocarcinomaBiopsy, NeedleFeasibility StudiesGene Expression ProfilingHumansMicroRNAsOligonucleotide Array Sequence AnalysisPancreatic NeoplasmsMicroRNAs

Identifiers

PMID22929886
PMCPMC3494446
OpenAlexW2088832018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.